Andere Sprachen Defence Therapeutics Inc.

Aktien

A3CN14

CA24463V1013

DTC

Verzögert Canadian Securities Exchange Andere Börsenplätze 18:31:24 25.04.2024			% 5 Tage	% 1. Jan.
1,23 ^CAD	0,00 %		-7,41 %	-46,35 %

26.03.	Defence Therapeutics Inc. gibt die erfolgreiche Erprobung des Anti-Krebs-Impfstoffs der zweiten Generation mit der Bezeichnung ARM-002TM bekannt	CI
01.03.	Defence Therapeutics Inc. gibt die Veröffentlichung einer von Experten begutachteten Studie über den Anti-Krebs-Impfstoff Accum-E7 in der Zeitschrift Cancer Science und ein Update zur Finanzierung bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation	23.04.
DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION	23.04.
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth	17.04.
DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH	17.04.
Defence Therapeutics Announces Warrant Terms Amendment	06.04.
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION	26.03.
Defence Therapeutics Inc. Announces the Successful Testing of Second-Generation Anti-Cancer Vaccine, Called ARM-002TM	26.03.
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine	26.03.
DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE	26.03.
Defence Completes 2nd Tranche of Financing	22.03.
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology	04.03.
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY	04.03.
Defence Therapeutics Inc. Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update	01.03.
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update	01.03.
Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	29.02.
Defence Therapeutics Completes 1st Tranche of Financing	31.01.
Defence Financing	20.01.
Defence Begins Trading on the OTCQB and Arranges Financing	13.01.
Defence Therapeutics Inc. announced that it expects to receive CAD 2.79 million in funding	12.01.
Defence Therapeutics Inc. Tests a New Formulation of its ACCUM-002TM Dimer CDCA-SV40 Commonly Named AccuTOX®	10.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Defence Therapeutics Inc.

Aktien

A3CN14

CA24463V1013

DTC

Andere Sprachen

Filter